1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Pfizer Inc.

Pfizer Inc.

PFE.DE
Pfizer Inc.DE flagDeutsche Börse
20.79
EUR
-0.60
- -
118.46BMarket Cap
Pfizer Inc.
PFE.DE
(Deutsche Börse)

Recent

price

20.79

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
8.11
7.81
7.34
7.57
7.82
7.91
8.68
8.8
6.95
7.35
7.5
14.51
18.04
10.55
11.23
11.01
11.13
Revenue per Share
1.03
1.28
1.96
3.23
1.44
1.13
1.18
3.57
1.9
2.88
1.65
3.92
5.59
0.38
1.42
1.37
1.32
Basic EPS, GAAP
1.24
2.35
2.06
2.38
2.44
2.14
2.33
2.44
2.33
1.82
2.1
5.33
4.64
0.85
1.74
1.6
1.67
Free Cash Flow per Basic Share
0.76
0.8
0.88
0.97
1.04
1.12
1.2
1.28
1.36
1.44
1.52
1.56
1.6
1.64
1.68
1.72
1.72
Dividend per Share
5.37
5.97
7.35
10.3
11.45
11.73
11.86
14.36
15.33
17.62
16.36
18.54
22.49
21.06
20.69
20.25
20.7
Book Value per Share
-1.65
-1.69
-0.96
-0.78
-0.89
-3.83
-7.76
-5.54
-4.24
-3.36
-2.6
0.55
0.21
-7.69
-6.26
-6.73
-5.9
Tangible Book Value per Share
8,036
7,817
7,442
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,608
5,643
5,664
5,683
5,687
Basic Weighted Avg Shares
65,165
61,035
54,657
51,584
49,605
48,851
52,824
52,546
40,825
40,905
41,651
81,288
101,175
59,554
63,627
62,579
63,314
Sales/Revenue/Turnover
25.41
27.54
31.24
31.73
27.21
26.56
25.95
26.78
16.48
17.87
22.84
29.16
37.67
7.42
23.48
27.82
27.24
Operating Margin (%)
8,399
9,026
7,655
6,410
5,537
5,157
5,757
6,269
6,150
5,755
4,681
5,191
5,064
6,290
7,013
6,592
6,587
Depreciation Expense
8,257
10,009
14,570
22,003
9,135
6,960
7,215
21,308
11,153
16,026
9,159
21,979
31,372
2,119
8,031
7,771
7,490
Net Income, GAAP
12.17
31.54
19.76
27.4
25.49
22.2
13.45
- -
- -
5.15
5.26
7.62
9.58
- -
- -
- -
4.86
Effective Tax Rate (%)
12.67
16.4
26.66
42.65
18.42
14.25
13.66
40.55
27.32
39.18
21.99
27.04
31.01
3.56
12.62
12.42
11.83
Profit Margin (%)
31,859
31,908
35,645
32,878
34,008
14,405
7,834
10,714
18,068
-4,501
9,147
17,022
9,121
-4,461
7,363
5,914
8,474
Working Capital
38,410
34,926
31,036
30,462
31,541
27,446
30,399
32,666
32,429
34,650
35,571
34,757
31,925
60,499
56,703
60,807
59,840
LT Debt
88,265
82,621
81,678
76,620
71,622
64,998
59,840
71,656
63,758
63,447
63,473
77,462
95,916
89,288
88,497
86,775
90,404
Total Equity
9.82
9
11.32
10.19
9.07
9.57
11.67
- -
- -
6.29
8.3
20.13
27.89
- -
- -
- -
10.54
Return on Invested Capital (%)
11.03
12.8
17.64
23
9.34
7.15
7.33
- -
- -
12.45
7.53
17.1
21.47
- -
- -
- -
5.5
Return on Capital (%)
19.65
22.28
28.75
35.24
12.79
9.59
9.97
26.97
12.69
17.03
9.69
22.57
27.28
1.73
6.8
6.69
6.3
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
4,303
3,154
3,890
LT Borrowings
56,545
60,807
59,840
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5,686
5,686
5,699
Market Capitalization
139,519
141,982
159,142

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
46,924
42,898
42,822
Cash, Cash Equivalents & STI
14,984
13,596
13,075
Accounts Receivable, Net
14,260
11,874
12,585
Inventories
11,468
10,654
10,667
Total Current Liabilities
36,596
36,984
34,348
Payables & Accruals
8,823
10,788
7,636
ST Debt
4,303
3,154
3,890
Deferred Revenue
924
784
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.65%
7.22%
-1.95%
Free Cash Flow
15.28%
31.94%
-7.73%
Net Income, GAAP
51.74%
73.04%
-3.24%
Sales/Revenue/Turnover
7.1%
16.73%
-1.65%
Total Cash Common Dividend
3.49%
2.97%
2.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
14,878
13,283
17,701
17,764
63,627
2025
13,715
14,653
16,654
17,557
62,579
2026
14,450
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.01
0.79
0.07
1.42
2025
0.52
0.51
- -
-0.29
1.37
2026
0.47
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.42
0.42
0.42
0.42
1.68
2025
0.43
0.43
- -
0.43
1.72
2026
0.43
- -
- -
- -
- -
Similar Companies
AbbVie Inc. (4AB.DE)
Beijing Biostar Pharms Co Ltd (2563.HK)
Flerie AB (publ) (FLERIE.ST)
Santen Pharmaceutical Co., Ltd. (4536.T)
Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ)
Grifols, S.A. (GRF.MC)
Business
Pfizer Inc. (NYSE: PFE; FSE: PFE.DE) develops, manufactures and markets biopharmaceutical products worldwide, including innovative prescription medicines, vaccines and consumer healthcare items; its core portfolio encompasses oncology therapies such as Ibrance (palbociclib), Padcev (enfortumab vedotin) and Elrexfio (elranatamab); internal medicine offerings including Eliquis (apixaban), Nurtec ODT (rimegepant) and Vyndamax (tafamidis); inflammation and immunology products such as Xeljanz (tofacitinib), Vyndaqel and Litfulo (ritlecitinib); vaccines like Comirnaty (COVID-19 mRNA vaccine), Prevnar 13/20 (pneumococcal conjugate vaccines), Abrysvo (RSV vaccine) and Trumenba (meningococcal group B vaccine); and sterile injectables, antibiotics, antivirals and cardiovascular drugs including Lipitor (atorvastatin), Norvasc (amlodipine) and Zithromax (azithromycin). The company, founded in 1849 by cousins Charles Pfizer and Charles F. Erhart and headquartered in New York City, operates globally across developed and emerging markets through manufacturing facilities, research centers and commercial operations in North America, Europe, Asia-Pacific and Latin America. In November 2025, Pfizer completed its acquisition of Metsera Inc. for approximately $7.0 billion plus a contingent value right tied to clinical and regulatory milestones, adding differentiated obesity and cardiometabolic candidates such as the Phase 3-ready GLP-1 receptor agonist MET-097i, the Phase 1 amylin analog MET-233i and an oral GLP-1 candidate to bolster its internal medicine pipeline amid post-pandemic strategic shifts.